HealthDay News – The percentage of patients with migraine reporting freedom from pain is higher for those receiving ubrogepant than those receiving placebo, according to a study published in the December 5 issue of the New England Journal of Medicine.

David W. Dodick, MD, from the Mayo Clinic in Phoenix, and colleagues randomly assigned adults with migraine, with or without aura, to receive either an initial dose of placebo (559 patients), ubrogepant 50mg (556 patients), or ubrogepant 100mg (557 patients) for treatment of a single migraine attack.

The researchers found that the percentage of patients with freedom from pain at 2 hours was 11.8, 19.2, and 21.2%, respectively, in the placebo, ubrogepant 50mg, and ubrogepant 100mg groups (P =.002 for ubrogepant 50mg versus placebo; P <.001 for ubrogepant 100mg vs placebo). The corresponding percentage of patients with freedom from the most bothersome symptom at two hours was 27.8, 38.6, and 37.7%, respectively (both P =.002). Within 48 hours after the initial or optional second dose, adverse events were reported in 12.8, 9.4, and 16.3%, respectively. Nausea, somnolence, and dry mouth were the most common adverse events; they were more frequent in the 100mg ubrogepant group.

Related Articles

“Trials evaluating consistency of effect, longer-term safety data, and comparative effectiveness are needed to assess the safety and clinical utility of ubrogepant for acute migraine treatment,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Allergan, which manufactures ubrogepant and funded the study.

Abstract/Full Text (subscription or payment may be required)